Management of rheumatoid arthritis (RA) in many Latin-American countries is impaired by fragmentation and scarce healthcare provision, resulting in obstacles to access, diagnosis, and treatment, and consequently in poor health outcomes. The aim of this study is to propose a comprehensive care program as a model to provide healthcare to RA patients receiving synthetic DMARDs in a Colombian setting by describing the model and its results. Health outcomes were prospectively collected in all patients entering the program. By protocol, patients are followed up during 24 months using a treat-to-target strategy with a patient-centered care (PCC) model, meaning that a patient should be seen by rheumatologist, physical and occupational therapist, physiatrist, nutritionist and psychologist, at least three times a year according to disease activity by DAS28. Otherwise, patients receive standard therapy. The incidence of remission and low disease activity (LDA) was calculated by periods of follow-up. A total of 968 patients entered the program from January 2015 to December 2016; 80.2% were women. At baseline, 41% of patients were in remission, 17% in LDA and 42% in MDS/SDA. At 24 months of follow-up, 66% were in remission, 18% in LDA and only 16% in MDS/SDA. Regarding DAS28, the mean at the beginning of the time analysis was 3.1 (SD 1.0) and after 24 months it was 2.4 (SD 0.7), showing a statistically significant improvement (p < 0.001). In all patients, the reduction of disease activity was 65% (95% CI, 58-71). Patients entering the PCC program benefited from a global improvement in disease activity in terms of DAS28.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune and inflammatory disease that affects joints and causes bone destruction [1, 2] . RA is a serious public health problem worldwide due to the severe disability caused by the disease, and the increased risk of dying [1, 2] .
The health systems in Latin America and Caribbean (LAC) are characterized by their heterogeneous structure and complex operational configuration, especially in the attention of chronic illnesses as RA [3, 4] .
In LAC with a population about 600 million people, there is a unmet need of 6000 specialists to treat RA because the World Health Organization recommends at least one rheumatologist per 100,000 people, in fact there are almost 3000 rheumatologists [4, 5] .
In Colombia, the situation of RA has been recently assessed, reporting issues in the attention of patients with RA [6] , mainly, the average time from the illness onset to the diagnosis is 7.96 years, and 23.8% of the RA patients did not have diagnostic confirmation studies. A rheumatologist cared only for 56% of cases in the country, and the median frequency of consultation was once a year. Also, 28-joint Disease Activity Score (DAS28) and health assessment questionnaire (HAQ) were only calculated in 39. 8 and 21 .3% of the patients, respectively [6] . Additionally, 65.1% of the patients were treated with synthetic DMARDs, 15 .5% in biologics, and another 19% receive only steroids [6] .
Currently, there is no uniform treatment of RA, and important non-response rates are reported for all commonly used drugs, including the non-biological and biological disease-modifying antirheumatic drugs (DMARDs) [7] . The ideal scenario would be the individualize treatment of patients to ensure remission is achieved rapidly, however, effective treatments are only identified by trial and error, sometimes even for prolonged periods of time [7] .
According to the Pan American Health Organization, today, healthcare for patients with chronic diseases is fragmented, showing a poorly developed provision of healthcare services, resulting in difficulties for access, diagnosis, treatment, and management of chronic patients [8] . One response to this fragmentation of healthcare is the creation of highly specialized health centers that concentrate and centralize the management of a single disease (in this case RA), also called Centers of Excellence (CoE) [9] . The CoE initiative for RA was recently proposed by the Panamerican League of Associations for Rheumatology (PANLAR), due to deficiencies in healthcare systems for management of chronic pathologies such as RA, where services demand exceeded supply, especially due to the geographical distribution of the patients, the low coverage of healthcare, and the low availability of specialists for management of chronic rheumatic diseases [4, 9] .
In 2010, the first recommendations on treat-to-target (T2T) were published, based both on evidence and expert opinion [10] . In 2014, these recommendations were reviewed and adjusted [11] . Our study shows evidence of the changes in health outcomes because of the application of a CoE-type, comprehensive model of patient-centered care (PPC) for management of RA in a rheumatologic institution in Bogotá, Colombia.
Methods
In Colombia, by express directive of the Ministry of Health through Resolution 1393 of 2015, it was established the mandatory report of demographic and clinical data of patients with RA to the High Cost Disease Fund of Colombia (Cuenta de Alto Costo, in Spanish) [12, 13] . We analyze this data concerning 2015-2016 years. Health outcomes were prospectively collected in all patients entering the program; by protocol, patients were followed up during 24-months using a treat-to-target strategy with a patient-centered care (PCC) model. The aim of study was to assess the effectiveness of a CoE-type comprehensive model according to the DAS28, following the cohort of patients from baseline up to for 24 months.
Center of Excellence model
The healthcare model proposed in our study is based on an adaptation of the Colombian Clinical Practice Guideline for the management of RA [14] . Under this model, patients with a diagnosis of RA are treated with synthetic DMARDs and followed by rheumatologist at least six times per year and by other allied professionals at least three times per year.
Assessment of changes in the health status of patients treated with the CoE model is performed by applying the DAS28 disease activity measurement scale [15] . The DAS28 score ranks RA patients into four health scales: < 2.6 for disease remission, between > 2.6 and < 3.2 for low activity (LDA), between ≥ 3.2 and ≤ 5.1 for moderate activity (MDA), and > 5.1 for severe activity (SDA) [15] . Depending on the DAS28 results, the decision about treatment and next appointment is taken. Figure 1 describes the flow of healthcare for patients with RA; the model used pre-assumes that appointments of patients are dynamic, i.e., healthcare depends on the activity status, although assistance to each of the other specialties involved at least three times a year is guaranteed.
The center of excellence denomination implies comprehensive healthcare for patients in several areas, with specialized appointments for: (1) rheumatology, with visits depending on the patient severity; (2) rehabilitation specialized medicine (≥ 3 times a year), (3) psychology (≥ 3 times a year), (4) physical and occupational therapy (≥ 3 times a year), (5) nutrition (≥ 1 time a year), and (6) pharmaceutical chemist (≥ 1 time a year). In addition, a patient safety program supplementary to these services consisting of a series of processes and procedures that seek to early prevent the onset of adverse events and/or the proper management of these when they appear is in place.
Analysis of the effectiveness of the program
Patients with RA were followed up for 24 months (from January 2015 to December 2016), and they were treated only with synthetic DMARDs (conventional therapy). Patients were referred from primary care centers by general practitioners and internists. As main healthcare outcome, the 28-joint Disease Activity Score was used, which was collected in each patient included [15] . Each patient was measured for their DAS28 several times during the follow-up.
We analyzed the progression of patients according to the stages of severity using four cutoff points, corresponding to measurements at baseline, 6, 12, and 24 months of follow-up.
Analyzes were performed by age and sex groups. Absolute and relative frequencies according to each cutoff group were estimated. Comparisons between groups of patients from baseline to 24 months of follow-up were performed using Kruskal-Wallis test for continuous variables, and crude odds ratios (OR) with their respective 95% confidence intervals (95% CI) were estimated using standard formula [16] . To calculate the potential reduction of non-remission symptoms in AR, we applied the following formula:
These comparisons were established by sex and age groups. Statistical analyzes were performed on R programming and Microsoft Excel 2016 ® .
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Results
A total of 968 patients were included in the study, 80.2% were women. The median age was 64 years [interquartile range (IQR), 57-71]. A 52.4% of patients received methotrexate, 26% leflunomide, and 21.6% other synthetic DMARDs. Baseline and clinical characteristics of patients are described in Table 1 . At 24-month follow-up, we found a significant improvement in treated patients according to DAS28. As of the time patients entered the program, 396 were already in remission, 161 in LDA, and 411 in MDA/SDA. At 24 months of follow-up, 642 stayed in remission, 175 in LDA, and 151 in MDA/SDA (see Fig. 2 ). By sex, men achieved remission more frequently than women. Both groups started in similar remission rates (40.7% women and 41.7% men), but by the end of the second year, men reached 79% remission and women stayed in 63% (Table 2) . By age group, the greatest improvement was seen in the age group of patients over 70 years old, where frequency went from 37.2% of patients in remission at baseline to 69.3% at 24 months (Table 3) . At the beginning of the analysis period, median DAS28 was 2.9 (IQR 2.3-3.7), and after 24 months it was 2.4 (IQR 2.1-2.8) showing a statistically significant improvement (p < 0.001). Figure 3 shows the odds ratios of the reduction of disease activity by sex and age groups at 24 months in patients included in the program. In all patients, reduction of severity was 65% (95% CI 58-71); in men, severity reduction was 81% (95% CI 70-88) and, in women, 60% (CI 95% 51-67). 
Discussion
This prospective study shows evidence of the reduction of disease activity using the T2T strategy in a CoE-type highly specialized rheumatologic center, and based on a PCC model to improve symptoms in patients with RA during 2 years of follow-up. Our results are similar to those obtained in studies carried out recently in other countries, where effectiveness of the T2T strategy was assessed [18] [19] [20] .
Under our knowledge, this is the first study in Colombia and LAC evaluating healthcare outcomes of patients diagnosed with RA treated under a CoE model. This comprehensive framework focuses on treating rather than the disease (PCC). If confirmed, our results have major implications in terms of health policies for the treatment of patients with RA in Colombia, suggesting the potential application of the proposed model in the Colombian healthcare system could dramatically improve quality of life in patients with RA.
A CoE model like the one presented is effective and efficient [21] [22] [23] [24] . Effective from the perspective that improves the results in patients' healthcare and efficient from an economic perspective. That is, improvement of patients prevents them from going to more serious stages of the disease, where treatments are more expensive in pharmacological terms and consumption of resources such as doctor's appointments and hospitalizations. Bearing in mind that a patient in a worse health situation results in higher indirect costs related to loss of productivity, especially in a disease that leads to a great extent of disability such as RA [25] .
A PCC model, as defined by the United States Medical Institute [26] , is one that provides respectful care, answering the patient's individual preferences, needs, and values, ensuring that these guide all clinical decisions [27] .
The philosophy behind a PCC model is the widespread respect for the patient as an individual entity in a social environment, which implies that they must be treated as individuals who need to be seen as multidisciplinary healthcare team members to ensure their considerations and requirements in health are taken into account [26] . Scientific evidence regarding the effectiveness of the PCC models compared to the traditional healthcare model shows that the degree to which the patients are most involved in their care has a significant impact on the quality of their treatment. At the same time, previous studies show this patient-oriented model can save costs to healthcare systems [26, 28] .
Studies on interventions that inform and involve patients in their healthcare show better results, with less dependence on healthcare services, and greater adherence to effective treatments [26, 29, 30] .
Consolidation of healthcare systems in the world had shifted from the attention of the patient to the attention of the disease, allowing for the creation of healthcare guides that facilitate the use of scale economies within the healthcare models centered under a biomedical perspective, where the healthcare professional is the center of the system, having exclusive access to information. In addition, the patient was expected to follow the instructions of the healthcare professional [26, 31] . A new consensus is emerging on the deficiencies of the previous paradigm [26, 32] , and newer recommendations state high-quality healthcare is a joint task between healthcare professionals and patients, always seeking to maintain and improve their health status [26, 33, 34] . With our CoE model, we have educated and empowered patients into their health, integrating them into participative medicine models.
Interestingly, we observed that patients with a better remission rates are men and people older than 70 years. We found similar results in other studies [35] . A possible explanation could be that older people and men are more adherent to the model and treatment than women, and women in Colombia fulfill multiple tasks, including housekeeping and working activities.
This study presents the limitations inherent to data collection and analysis, in which the completeness of the information generates restrictions for the assessment of the results. However, with clearly defined inclusion criteria, the analysis of a cohort with a significant number of patients was achieved, which ensures the robustness of our results. Another important limitation of the study is the difficultness to calculate the specific weight of each specialty involved in healthcare for the improvement of the patient. We consider that rheumatology appointments and the strict application of the treat-to-target by themselves would contribute by 60-70% of that improvement, but the aforementioned would have to be confirmed [36] .
Promotion of prospective and multicenter comparative studies assessing results from groups of patients treated under different healthcare strategies, and additionally, the review of sanitary policies that consider the best decisions for care of patients with this pathology are recommended.
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